Palomar Holdings, Inc. (NASDAQ:PLMR – Get Free Report) CEO Mac Armstrong sold 5,000 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $129.00, for a total value of $645,000.00. Following the completion of the transaction, the chief executive officer directly owned 348,388 shares of the company’s stock, valued at $44,942,052. This represents a 1.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Mac Armstrong also recently made the following trade(s):
- On Thursday, January 15th, Mac Armstrong sold 2,310 shares of Palomar stock. The stock was sold at an average price of $130.00, for a total value of $300,300.00.
- On Friday, November 21st, Mac Armstrong sold 5,000 shares of Palomar stock. The shares were sold at an average price of $122.86, for a total value of $614,300.00.
Palomar Trading Down 2.3%
PLMR stock opened at $124.95 on Friday. Palomar Holdings, Inc. has a twelve month low of $101.64 and a twelve month high of $175.85. The company has a market capitalization of $3.31 billion, a P/E ratio of 19.49 and a beta of 0.42. The firm has a 50 day simple moving average of $127.91 and a 200-day simple moving average of $124.43.
Institutional Investors Weigh In On Palomar
Large investors have recently added to or reduced their stakes in the stock. Salomon & Ludwin LLC acquired a new position in shares of Palomar during the third quarter valued at $25,000. Richardson Financial Services Inc. lifted its position in Palomar by 210.0% in the 3rd quarter. Richardson Financial Services Inc. now owns 217 shares of the company’s stock valued at $25,000 after purchasing an additional 147 shares during the last quarter. Allworth Financial LP lifted its position in Palomar by 1,970.0% in the 2nd quarter. Allworth Financial LP now owns 207 shares of the company’s stock valued at $32,000 after purchasing an additional 197 shares during the last quarter. Maseco LLP acquired a new position in Palomar during the 2nd quarter valued at about $45,000. Finally, Clearstead Advisors LLC grew its position in Palomar by 31.0% in the 3rd quarter. Clearstead Advisors LLC now owns 397 shares of the company’s stock worth $46,000 after purchasing an additional 94 shares during the last quarter. 90.25% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on PLMR shares. Wall Street Zen upgraded Palomar from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Evercore ISI reduced their target price on Palomar from $168.00 to $134.00 and set an “in-line” rating on the stock in a report on Wednesday, October 1st. Weiss Ratings upgraded Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, January 14th. Keefe, Bruyette & Woods boosted their price target on Palomar from $170.00 to $171.00 and gave the company an “outperform” rating in a report on Tuesday, January 6th. Finally, JPMorgan Chase & Co. upped their price target on Palomar from $145.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $159.50.
Get Our Latest Stock Report on Palomar
Palomar Company Profile
Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.
In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.
Read More
- Five stocks we like better than Palomar
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- Your Signature Is Missing – Act Before It’s Too Late
- The $100 Trillion AI Story No One Is Telling You
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Palomar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palomar and related companies with MarketBeat.com's FREE daily email newsletter.
